CVS Health Corporation
CVS Health Corporation (CVS)
Overview
CVS Health Corporation is an American healthcare conglomerate headquartered in Woonsocket, Rhode Island, often described as the second-largest healthcare company in the world by revenue, behind UnitedHealth Group. Founded in 1963 in Lowell, Massachusetts by brothers Stanley and Sidney Goldstein and Ralph Hoagland as "Consumer Value Stores," a health-and-beauty retailer, the company went public in 1996 and transformed into an integrated healthcare enterprise through major acquisitions — Caremark (2007, pharmacy benefit management), Aetna (2017, $69 billion, health insurance), Signify Health (2022, $8 billion), and Oak Street Health (2023, $10.6 billion, primary care). CVS Health now generates roughly $400 billion in annual revenue (fiscal 2025), employs approximately 300,000 people, operates about 9,100–9,600 retail pharmacy locations across all 50 states, and carries a market capitalization in the range of $90–100 billion — a valuation that reflects thin margins on enormous revenue, typical of the healthcare-benefits and pharmacy-distribution industries.
What They Do & How They Make Money
CVS Health makes money across nearly every step of the U.S. healthcare and pharmacy value chain simultaneously. Its health insurance arm (Aetna) collects premiums from employers, individuals, and government programs (Medicare Advantage, Medicare Supplement, Medicaid) in exchange for covering members' medical and pharmacy costs — profit comes from the spread between premiums collected and claims paid plus administrative costs, a margin the industry calls the medical benefit ratio. Its pharmacy benefit manager (Caremark) is hired by employers and health plans to negotiate drug prices with manufacturers, build pharmacy networks, and process prescription claims, earning fees, rebates, and spread pricing on the tens of billions of dollars in prescription drug spending it administers on clients' behalf. Its retail pharmacy business fills prescriptions and sells front-of-store health, beauty, and convenience products directly to consumers — CVS states it fills more than one in five prescriptions dispensed in the United States — earning dispensing fees, drug margins, and retail merchandise margins, reinforced by the roughly 70-million-member ExtraCare loyalty program. Increasingly, CVS also earns revenue from direct healthcare delivery — MinuteClinic walk-in clinics, Oak Street Health primary-care centers (largely serving Medicare patients), and Signify Health's in-home health assessments — positioning the company to capture value from actually providing care, not just financing or dispensing around it. The strategic logic of owning insurer, PBM, pharmacy, and provider under one roof is "vertical integration": CVS can theoretically manage a patient's costs and care more efficiently across the whole chain than a company operating in only one layer, capturing margin at each step.
Business Segments
CVS Health reports three segments:
- Health Care Benefits (~$143 billion FY2025 revenue): Aetna's health insurance operations, covering roughly 22 million medical members through commercial, Medicare Advantage, Medicare Supplement, and Medicaid managed-care plans. This segment has been the primary source of recent earnings pressure, as Medicare Advantage medical costs have risen faster than premium pricing could adjust.
- Health Services (~$190 billion FY2025 revenue, the largest segment): anchored by CVS Caremark's pharmacy benefit management business serving roughly 75 million plan members, alongside MinuteClinic (1,100+ locations), Oak Street Health primary care, and Signify Health's in-home care assessment business.
- Pharmacy & Consumer Wellness (~$139 billion FY2025 revenue): the retail pharmacy chain (~9,100–9,600 stores) filling prescriptions and selling over-the-counter health, beauty, and convenience products, along with specialty pharmacy services and the ExtraCare loyalty program.
Segment revenue totals roughly $470 billion before intersegment eliminations bring reported consolidated revenue down to about $400 billion, reflecting the substantial internal business CVS does with itself (e.g., Caremark routing prescriptions to CVS retail pharmacies, Aetna members using CVS pharmacies). Profitability is thin and has compressed: trailing operating margin sits around 3%, down from roughly 4% in fiscal 2023, and fiscal 2025 net income fell sharply (down over 60% year over year) as Medicare Advantage medical costs outpaced premiums.
Competitors
- Integrated healthcare/insurance conglomerates: UnitedHealth Group (Optum + UnitedHealthcare) is CVS's closest direct analog and largest rival, competing across insurance, PBM (OptumRx), and care delivery; Cigna Group (Evernorth/Express Scripts PBM plus health insurance) and Elevance Health are also close comparables.
- Pharmacy benefit management: Express Scripts (Cigna/Evernorth) and OptumRx (UnitedHealth) are Caremark's two main PBM rivals, together forming a PBM "big three" that has drawn regulatory and legislative scrutiny over drug pricing practices.
- Retail pharmacy: Walgreens Boots Alliance is CVS's primary retail pharmacy competitor, along with Walmart, Kroger, Costco, and Amazon Pharmacy in prescription and front-store retail.
- Health insurance: Humana (especially in Medicare Advantage), Centene, and Molina Healthcare compete in government-sponsored plans; Blue Cross Blue Shield affiliates compete broadly in commercial insurance.
- Diagnostics/other health services: Labcorp and Quest Diagnostics compete in lab and diagnostic services adjacent to CVS's care-delivery ambitions; DaVita competes in specialty care delivery.
Competitive Position
CVS Health's central competitive advantage is scale and vertical integration: owning an insurer, a PBM, a nationwide pharmacy footprint, and a growing primary-care network under one company lets it theoretically manage costs and steer patients across its own assets — for example, routing Aetna members and Caremark clients' patients into CVS pharmacies and Oak Street clinics — in ways that single-layer competitors cannot. Its retail pharmacy density and brand recognition give it a consumer touchpoint that PBM-only or insurer-only competitors lack, and its ExtraCare loyalty base and MinuteClinic network extend that reach into everyday consumer health. The Oak Street Health and Signify Health acquisitions reflect a deliberate strategic push into value-based, in-home, and primary care aimed at capturing more of the healthcare dollar and improving outcomes (and therefore costs) for its highest-cost members, particularly in Medicare Advantage.
That said, CVS faces serious and current headwinds. Medicare Advantage margin compression — medical costs (particularly for higher-acuity, higher-cost members) rising faster than CMS reimbursement and premiums — has been the single largest driver of recent earnings disappointment and a sharp net income decline in fiscal 2025. The PBM industry as a whole, including Caremark, faces mounting regulatory and legislative scrutiny in the U.S. over drug pricing transparency, rebate practices, and potential structural reforms that could compress PBM economics. CVS also carries substantial legacy legal exposure, having paid an estimated $7+ billion in settlements and penalties over the past 25 years, including opioid-distribution litigation and pharmacy fraud cases, plus newer lawsuits and state investigations over 340B drug-pricing practices. Its retail footprint has been contracting — the company has closed hundreds of stores in response to shifting consumer shopping habits and pharmacy economics — and it has been exiting unprofitable ACA individual insurance markets while pivoting further toward Medicare Advantage and healthcare technology, including a stated roughly $20 billion technology investment plan and new GLP-1 weight-loss drug partnerships, as it works to stabilize margins and restore investor confidence.